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ABSTRACT  
Objective: This study was designed to prepare and characterize oil in water (o/w) nanoemulsion of candesartan cilexetil for oral administration. 
Preparation of candesartan cilexetil as nanoemulsion could increase its water solubility and thus could enhance its bioavailability.  
Methods: Aqueous titration method was used to construct the pseudo-ternary phase diagrams of nanoemulsion (NE) consisting of oil, various 
weight ratios of surfactant and co-surfactant (S mix), and deionized water. Different characterization techniques were conducted on the prepared 
nanoemulsions to obtain the optimized formula. 
Results: Characterizations of formula NE-4 (consists of 0.16% of candesartan cilexetil, 10% of garlic oil, 35 % of S mix (3:1) and 54.84% of 
deionized water) revealed the following characteristics: droplet size range (95-139 nm), polydispersity index (0.14), zeta potential value (-41.06 
mV) and pH value (6.71), which are suitable for oral administration. Candesartan cilexetil in vitro release from this formula was significantly high 
(P<0.05) and scanning probe microscopy (SPM) study confirmed that the optimized formula (NE-4) was in nano-scale.  
Conclusion: Nanoemulsion formula 4 (NE-4) of candesartan cilexetil is the optimized formula and it could be a promising formula for improving the 
water solubility of candesartan cilaxetil.  
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Oral conventional dosage forms are designed to provide a rapid 
onset via an immediate release of the active ingredient after 
administration. The desired therapeutic action, which can be 
achieved from these conventional drug delivery system, is based on 
the bioavailability of drugs. Bioavailability of immediate-release 
products is influenced by two important drug characteristics, which 
are water-solubility and permeability. Dissolution rate in the 
conventional dosage forms that contain a drug with low water 
solubility would be low, hence the bioavailability may be affected 
due to lower absorption across the gastrointestinal tract [1]. Based 
on permeability and water solubility, four classes of drugs are 
classified by Biopharmaceutics Classification System (BCS) into class 
I includes drugs with high permeability and high water solubility, 
class II includes drugs with high permeability and low water 
solubility, class III includes drugs that possess low permeability and 
high water solubility and class IV includes drugs with low 
permeability and low water solubility [2].  
Enhancing water solubility of drugs belonging to class II using 
different techniques, such as self-emulsification, particle size 
reduction, and nanotechnology approaches, have the potential to 
improve absorption and thus enhance oral bioavailability of these 
drugs [3]. An example of these techniques is a nanoemulsion, which is 
a colloidal dispersion system consisting of oil, water, and surfactant 
and co-surfactant [4]. This system (nanoemulsion) is a 
thermodynamically stable system and is available in three different 
types: oil in water (o/w), water in oil (w/o) and bi-continuous 
nanoemulsions, where the microdomains of the two phases (water 
and oil) are inter-dispersed within the system [4]. Stabilization of all 
three nanoemulsion types is achieved via the presence of a good 
amount of surfactant and co-surfactant [4]. Based on the fact that this 
system (nanoemulsion) is prepared with a little energy input and has a 
long shelf life, it has a higher thermodynamic stability and 
solubilization capacity than other micellar solutions. Additionally, 
nanoemulsion can enhance the transport characteristic of drug, which 
is crucial for sustained and targeted drug delivery owing to their 
numerous interfacial area associated with this system [5]. Examples of 
successful implementation of nanoemulsion in enhancing water 
solubility have been reported previously, which were; oral 
nanoemulsion of rosuvastatin, rifampicin, and pterostilbene [6–8].  
Candesartan cilexetil, a selective angiotensin II receptor subtype 
inhibitor, belongs to BCS class II with low water solubility and high 
permeability, while its oral bioavailability is only 14-40% [9]. Hence, 
this study was aimed to develop, optimize, and characterize 
candesartan cilexetil oral oil in water (o/w) nanoemulsion to 
improve its solubility and possibly the bioavailability.  
MATERIALS AND METHODS 
Materials 
Pure candesartan cilexetil powder was purchased from Hyper chem 
company, China. Tween 20, tween 60 and tween 80 were purchased 
from Thomas baker (chemicals) Pvt Ltd, India. Olive oil was supplied 
by Pomace olive oil, oilex, S. A, Spain. Polyethylene glycol 400 and 
propylene glycol were supplied by M/s provizer pharma, India. 
Ethanol was supplied by Avantor performance materials, Norway. 
Garlic oil and peppermint oil were purchased from Al-Emad 
Company, Iraq. Soybean oil was obtained from Genuine chemicals, 
India. Castor oil and deionized water were supplied by Al-Basheer 
company for chemical and laboratory materials, Baghdad, Iraq. 
Methods 
Melting point measurement  
Candesartan cilexetil melting point was recorded by inserting a small 
amount of pure powdered drug into one side of a sealed capillary glass 
tube. By using a digital melting point instrument, the temperature of 
melting was recorded when all the powdered drug has melted [10].  
Study of differential scanning calorimetry  
Differential scanning calorimeter (DSC) technique was made by 
placing a sample of the drug (5 mg) in the aluminum pan of DSC-60 
Shimadzu. Analysis of this technique was made by using nitrogen at 
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a rate of 10/min as inflow gas with heating range 50–250. DSC 
thermogram of candesartan cilexetil was recorded [11]. 
Study of saturated solubility 
The saturated solubility of candesartan cilexetil was determined in 
various surfactants (tween 20, tween 60 and tween 80), co-
surfactants (polyethylene glycol 400 and propylene glycol) and oils 
(olive oil, garlic oil, peppermint oil, castor oil, and Soybean oil). 
Excess amount of powdered drug was added to 2 ml of each 
surfactant, co-surfactant, and oil in tightly closed plain tubes. The 
tubes were placed in an isothermal shaker water bath at 25±0.5 for 
48 h. Then the samples were centrifuged at 2000 rpm for 10 min and 
supernatants for each sample were filtered by using filter membrane 
(0.45 µm). After dilution of filtrate with ethanol, solubility was 
measured using a UV-visible spectrophotometer in determined 
maximum wavelength [12].  
Construction of pseudo-ternary phase diagrams 
Aqueous titration method was utilized to determine the components 
of pseudo-ternary phase diagrams. These components include a 
mixture of surfactant and co-surfactant (S mix), oil and deionized 
water. Different weight ratios (2:1, 3:1, and 4:1) were used for the 
mixing of surfactant and co-surfactant (S mix). Oil and S mix was 
blended in different weight ratios until the maximum ratio of oil and 
S mix was obtained. Fifteen different combinations of S mix and oil 
were prepared, then these combinations slowly titrated with 
deionized water and visual inspection was made for transparency. 
The titration was stopped when clear and transparent oil in water 
(o/w) nanoemulsion was produced [13].  
Preparation of the candesartan cilexetil loaded nanoemulsions 
Candesartan cilexetil pure powder was dissolved in the oil that had 
the highest solubility for the drug, after that the quantity of S mix 
prepared from mixing of surfactants with co-surfactant was added to 
the oil loaded with the drug. Vortex mixer was used to blend the 
components of the whole mixture. Then titration of deionized water 
(drop by drop) on the mixture was made until clear (o/w) 
nanoemulsion is produced [14].  
Thermodynamic stability tests of the prepared nanoemulsions 
Centrifugation test: Nanoemulsions were centrifuged for 15 min at 
2000 rpm and checked for phase separation or cracking [15]. 
Freezing–thawing test: This test involved exposure of nanoemulsions 
to different temperatures, which were 21 °C and freeze using a 
refrigerator with no less than 24 h for each temperature.  
Heating-cooling test: This test was made by keeping 
nanoemulsions at 40 °C and 0 °C by the refrigerator. The time for 
each temperature was no less than 48 h. In this test, the cracking 
effect on nanoemulsion stability was reported 
Characterization of nanoemulsion  
Droplet size measurement 
Droplet size was measured using particle size analyzer ABT-9000 
nanolaser. The droplet size and the plot for the distribution of the 
droplets were reported [16]. 
Polydispersity index (PDI) measurement 
(PDI) measurement was made utilizing particle size analyzer ABT-9000 
nanolaser. This PDI determination indicates the distribution of droplets 
is within the nanoemulsion scale and determines the uniformity of 
droplets, i.e. higher value indicates lower uniformity [17].  
Zeta potential (ZP) measurement 
Determination of zeta potential was made using zeta sizer instrument 
(Brookhaven). Zeta potential refers to the stability of colloidal 
dispersions, hence it describes the charge on the droplet surface [18].  
Percent of transmittance measurement (% T) 
This measurement was performed using a UV-visible 
spectrophotometer (Emc Lab. UV-61 Double beam, Germany). The 
transmittance of the prepared nanoemulsions was measured at 650 
nm using deionized water as a blank [19].  
pH measurement 
pH of the prepared nanoemulsions was reported using digital pH 
meter (BP 3001, Trans instruments, Singapore), the measurement 
was made in triplicate [20]. 
Viscosity measurement 
Viscosity measurement was made using NDJ-digital viscometer 
(spindle no. 1) at 25. The viscosity was measured without making 
any formulation dilution [21]. 
In vitro release study 
In vitro release of candesartan cilexetil nanoemulsion was studied 
using dissolution apparatus USP-II (Copley dissolution tester DIS 
8000, UK) with dialysis bag. Amount of candesartan cilexetil was 8 
mg in each nanoemulsion formula (5 g). Each formula was placed in 
the dialysis bag and the dialysis bag was immersed in 900 ml of 
dissolution medium. The dissolution medium was phosphate buffer 
(pH 6.8). The apparatus was set at 37±0.5with rotation velocity of 50 
rpm for 2 h. One Sample (5 ml) was withdrawn every 15 min for 2 h 
and was replenished by 5 ml of fresh medium to maintain sink 
condition. All samples withdrawn were filtered using filter 
membrane (0.45 µm). Then, samples were analyzed using a UV-
visible spectrophotometer at 255 nm to determine the candesartan 
cilexetil amount in the formula [22]. 
Kinetics and mechanism of drug release 
Various kinetics models were applied to the data obtained from in 
vitro release study to determine kinetics and mechanisms of drug 
release. These models are zero-order, first-order, Higuchi’s and 
Korsmeyer’s model [23]. 
Scanning probe microscopy (SPM) 
SPM (triple probe microscope) study was made to show the 
morphology of the droplets and droplets distribution within the 
prepared system. A drop of nanoemulsion was placed on a glass 
slide where detection was made [24].  
Statistical analysis  
Analysis of variance test (ANOVA) was used to analyze the data. 
Variables with P-value>0.05 were considered statistically 
insignificant. 
RESULTS AND DISCUSSION  
The melting point of the drug  
The melting point of candesartan cilexetil was found in the range of 
(171–172). This result was similar to that reported in the literatures, 
which indicates the purity of the powdered drug used in the study [25]. 
Differential scanning calorimetry (DSC) 
Candesartan cilexetil pure powder produced a sharp peak at 172.29 
[26]. This reading corresponds with the measured melting point of 
candesartan cilexetil. DSC thermogram explained in fig. 1. 
Saturated solubility  
The preparation of stable nanoemulsion requires a suitable selection 
of components forming the formulas. Using a saturated solubility 
study of candesartan cilexetil in different oils, surfactants, and co-
surfactants, the main components of the formulation can be selected. 
Hence, the formulation components which have the highest 
solubility for candesartan cilexetil were chosen as the main 
components in the preparation. Garlic oil had the highest solubility 
for the drug as compared with other oils used in this study, hence it 
was used as an oil phase in the formulation. Similarly, Tween 80 and 
polyethylene glycol 400 (PEG400) had the highest solubility for the 
candesartan cilexetil, hence tween 80 was used as surfactant and 
PEG400 was used as co-surfactant in the formulation [7]. The results 
of the saturated solubility of candesartan cilexetil in various oils, 
surfactants, and co-surfactants are explained in fig. 2. 
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Fig. 1: DSC thermogram of candesartan cilexetil pure powder 
 
 
Fig. 2: Saturated solubility of candesartan cilexetil pure powder in different oils, surfactants, and co-surfactants 
 
 
Fig. 3: Pseudo–ternary phase diagram of garlic oil, Smix 2:1 and deionized water 
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Fig. 4: Pseudo–ternary phase diagram of garlic oil, Smix 3:1 and deionized water 
 
 
Fig. 5: Pseudo–ternary phase diagram of garlic oil, Smix 4:1 and deionized water 
 
Construction of pseudo-ternary phase diagrams 
Pseudo-ternary phase diagrams were plotted using the component 
which had the highest solubility for candesartan cilexetil. Garlic oil 
was chosen as the oil phase both because of its high solubility to the 
drug and its benefits to patients with cardiovascular diseases, 
especially hypertension [27], which is one of the most important 
clinical indication of candesartan cilexetil. Tween 80 as a surfactant, 
polyethylene glycol 400 (PEG400) in S mix ratio (2:1, 3:1 and 4:1) 
and deionized water were selected as the aqueous phase in the 
formulation. Pseudo-ternary phase diagrams with different S mix 
ratios are shown in fig. 3-5, where the colored area in the plot was 
regarded as the area of nanoemulsion. 
Preparation of candesartan cilexetil loaded nanoemulsion 
Candesartan cilexetil loaded nanoemulsions were prepared by 
dissolving 0.16 g of the drug in the determined quantities of oil and S 
mix to prepare a formula of 100 g, which means that 8 mg of drug 
was in a formula of 5 g. Drug-loaded nanoemulsions are explained in 
table 1. 
Thermodynamic stability tests of the prepared nanoemulsions 
All preparations of drug-loaded nanoemulsions were successfully 
passed through the tests of dispersion stability, where the 
appearance of phase separation or cracking effect was not reported. 
Six nanoemulsions with different S mix ratios were selected for 
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characterization study. These nanoemulsions were F1 (NE-1), F2 
(NE-2), F6 (NE-3), F7 (NE-4), F11 (NE-5) and F12 (NE-6). The 
selection was made based on the low percentage of S mix and high 
percentage of deionized water [28]. 
  
Table 1: Composition of candesartan cilexetil loaded nanoemulsions (F1-F15) 
S mix ratio Formula code Garlic oil 
% w/w 




Deionized water %w/w 
 
2:1 
F1 10 20 (13.33:6.66) 0.16 69.84 
F 2 10 30 (20:10) 0.16 59.84 
F 3 10 35(23.33:11.66) 0.16 54.84 
F 4 15 40 (26.66:13.33) 0.16 44.84 
F 5 15 45 (30:15) 0.16 39.84 
 
3:1 
F 6 10 30 (22.5:7.5) 0.16 59.84 
F 7 10 35 (26.25:8.75) 0.16 54.84 
F 8 10 40 (30:10) 0.16 49.84 
F 9 15 45 (33.75:11.25) 0.16 39.84 
F 10 15 55 (41.25:13.75) 0.16 29.84 
 
4:1 
F 11 10 30(24:6) 0.16 59.84 
F 12 10 40 (32:8) 0.16 49.84 
F 13 15 50 (40:10) 0.16 34.84 
F 14 15 55 (44:11) 0.16 29.84 
F 15 10 65 (52:13) 0.16 24.84 
 
Characterization of nanoemulsions  
Droplet size measurement  
The results of droplet size measurement of the six drug-loaded 
nanoemulsions are shown in table 2. The results indicate that all the 
nanoemulsions were observed in a nano-size scale. Furthermore, as 
the ratio of S mix increases, the droplet size decreases. Such 
observations can be attributed to the fact that the lipophilic tail of 
surfactant (tween 80) in the drug-loaded nanoemulsions is pulled 
toward the drug and the drug makes an insertion of co-surfactant 
between the cavities of surfactant causing a condensation of interfacial 
film, stabilization, and production of droplets in a small size [29]. 
According to the analysis of variance (ANOVA) test, there was a 
significant effect of S mix ratio on the droplet size (P-value<0.05). 
Polydispersity index (PDI) measurement  
The results of the PDI measurement of the six drug-loaded 
nanoemulsions are explained in table 2. A typical range of PDI of (0-
1) indicates the uniformity of droplet size distribution within the 
formulations. In this study, the values of the drug-loaded 
nanoemulsions PDI were less than one, which explains the 
uniformity and distribution of the droplets dispersed in the garlic oil 
globules within the nanoemulsions [30].  
Zeta Potential (ZP) Measurement 
The results of the ZP measurement of the six drug-loaded 
nanoemulsions are explained in table 2. Zeta potential is an important 
indicator of colloidal dispersions stability. Rule of thumb explains the 
zeta potential effect on the stability of nanoemulsion. This rule 
indicates that: fast droplets aggregation occurs when values of zeta 
potential are (-5 to+5 mV), values of (≤-20 to ≥+20 mV) indicate short-
term stability, while values of (≤-30 to ≥+30 mV) indicate good system 
stability. Excellent stability within formulation can be obtained when 
ZP values in the range of (-60 to+60 mV) [31]. In this study, NE-1 and 
NE-2 were within short stability, while NE-3, NE-4, NE-5, and NE-6 
were in the range of good stability. 
  
Table 2: Characteristics of nanoemulsions (Droplet size, PDI, ZP) 
NE–code Droplets size range (nm) Polydispersity index (PDI) Zeta potential (ZP) (mv) 
NE 1 315-397 0.09 -23.12 
NE 2 281-397 0.06 -28.70 
NE 3 223-315 0.01 -35.10 
NE 4 95-139 0.14 -41.06 
NE 5 37.4-123 0.03 -45.53 
NE 6 16.6-93.2 0.15 -39.13 
 
Percent of transmittance measurement (%T) 
Percent of transmittance of the six drug-loaded nanoemulsions are 
illustrated in table 3. Values of all nanoemulsions were higher and 
closer to 100%, which indicates the clarity and transparency of the 
nanoemulsions [5]. The highest value of percent of transmittance 
was (99.313±0.011 %), which belongs to the formula (NE-4). The 
lower value of (%T) was (98.151±0.102), which belongs to the 
formula (NE-1). According to (ANOVA) test, there was no significant 
difference (P-value>0.05) in the percent of transmittance values 
among all the six drug-loaded nanoemulsions. 
pH measurement  
The results of the pH measurement of all six drug-loaded 
nanoemulsions are explained in table 3. The pH values of all 
nanoemulsions were higher than (5.5), which can be attributed to 
the high percentage of the aqueous phase and the slight basic 
properties of an oil phase (garlic oil). This could convey the 
suitability of the formulations for oral administration. According to 
(ANOVA) test, there was no significant difference (P-value>0.05) in 
pH values between all drug-loaded nanoemulsions. 
Viscosity measurement 
Viscosity values of all drug-loaded nanoemulsions are shown in table 
3. The viscosity of all nanoemulsions was found in the range of 
(58.232 mPa. s) for NE-2 and (36.175 mPa. s) for NE-4. There was a 
significant difference (P-value<0.05) in the viscosity values of the 
nanoemulsions. This reveals that all the nanoemulsions are easily 
poured and are suitable for an oral administration. 
In vitro release study  
The release of the prepared candesartan cilexetil nanoemulsions 
(NE-1-NE-6) is illustrated in fig. 6. Drug release profile of the 
nanoemulsions (NE-1, NE-2, NE-3, NE-4, NE-5 and NE-6) in the 
dissolution medium (phosphate buffer, pH 6.8) signalized drug 
release in an order of: NE-4>NE-3>NE-1>NE-2>NE-6>NE-5. Higher 
release of candesartan cilexetil was observed in NE-4 with garlic oil: 
S mix: deionized water of (10: 35: 54.84), in which S mix was (3:1). 
In contrast, lower drug release was observed in NE-6 with garlic oil: 
S mix: deionized water of (10:40:49.84), in which S mix was (4:1). It 
has been further noticed that as S mix ratio increases, the release of 
the drug would increase, yet to a certain limit as was noted with S 
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mix 2:1 and S mix 3:1. Furthermore, the release of the drug 
decreases with increase S mix as in 4:1, and this can be attributed 
both to a high concentration of surfactant, which would make drug 
molecules to challenge the retarding effect resulting from the 
surfactant, and to the increase in the surfactant concentration, which 
could raise the diffusion of a drug from dialysis bag to the 
dissolution medium [8]. 
There was a significant effect (P-value<0.05) between the 
concentration of surfactant and drug release. 
  
Table 3: Characteristics of nanoemulsions, pH and %T (mean±SD, n= 3). 
NE–code % Transmittance (%t) pH Viscosity (mPa. s) 
NE 1 98.151±0.102 5.63±0.021 51.413 
NE 2 98.211±0.034 5.97±0.003 58.232 
NE 3 99.012±0.032 6.13±0.021 40.435 
NE 4 99.313±0.011 6.71±0.108 36.175 
NE 5 98.843±0.103 6.20±0.102 46.215 
NE 6 98.511±0.120 6.28±0.099 43.651 
 
 
Fig. 6: In vitro release of candesartan cilexetil nanoemulsions with different Smix ratio 
 
Kinetics and mechanism of drug release 
To determine the kinetics and mechanism of drug release, release 
data were fitted to various kinetic models (i.e. zero order, first order, 
Higuchi’s and Korsmeyer’s model). Higher regression coefficient (R2) 
values could represent the kinetics of drug release from 
nanoemulsions. The mechanism of drug release was determined by 
fitting release data to Korsmeyer-Peppa's model (equation 1). 
Furthermore, diffusion exponent (n) values were further 
determined. According to the values of the diffusion exponent (n), 
the mechanism of drug release can determined as following: n value 
of 0.43 or less, the release of drug was Fickian release 
(diffusion)/(case I), n value larger than 0.43 but less than 0.89, the 
release of drug was Non-fickian release (diffusion and erosion), n 
value of 0.89, the release of drug was zero-order release 
(erosion)/(case II), and n value larger than 0.89, the release of drug 
would follow super release [23].  
The values of the regression coefficient (R2) and diffusion 
exponent (n) of candesartan cilexetil nanoemulsions were 
explained in table 4. In this study, higher regression coefficient 
(R2) values were obtained in Higuchi’s model; hence the kinetics 
of drug release in all nanoemulsions would follow Higuchi’s 
model. The values of diffusion exponent (n) of all nanoemulsions 
were significantly lower than 0.43 (P-value<0.05), which 
indicates that mechanism of drug release from all nanoemulsions 
is Fickian release (diffusion)/(case I). 
Equation1 
Where: F fraction of drug released at the time (t), Mt is the amount 
of drug released at the time (t), M is total amount in the dose age 
form, Km constant and (n) is the diffusion exponent describes the 
type of mechanism for drug release. 
Characterization of the candesartan cilexetil nanoemulsions 
optimized formula  
Characterizations of the candesartan cilexetil nanoemulsions 
indicate that NE-4 was the optimized formula. This formula had a 
droplet size of (95-139 nm) (fig. 7), PDI of (0.41), pH value of (6.71), 
viscosity value of (36.175 mPa. s), and a good drug release (98%). 
These characterizations indicate that NE-4 formula was a suitable 
formula for oral administration. The optimized formula NE-4 had 
good stability based on the rule of thumb because of the zeta 
potential value, which was (-41.06 mV) as explained in fig. 8. 
Scanning probe microscopy (SPM) of the optimized formula  
The morphology of the optimized formula (NE-4) of candesartan 
cilexetil nanoemulsion was determined in this study, which was 
spherical in shape, the size of droplets was similar to size that 
obtained by particle size analyzer ABT-9000 nanolaser, aggregation 
doesn’t present between the droplets. Hence, this optimized formula 
(NE-4) possess good stability. Droplets morphology of the optimized 
formula is explained in fig. 9, and the cumulative distribution chart 
of droplets within the optimized formula is shown in fig. 10. 
 
Table 4: Kinetic analysis data of the release profile of candesartan cilexetil nanoemulsions 
NE-code Zero-order model First-order model Higuchi-model Korsmeyer-peppas model Diffusion exponent 
 R2 R2 R2 R2 N 
NE-1 0.956 0.901 0.991 0.911 0.29 
NE-2 0.956 0.899 0.995 0.908 0.41 
NE-3 0.946 0.876 0.992 0.921 0.36 
NE-4 0.925 0.823 0.992 0.901 0.32 
NE-5 0.957 0.902 0.997 0.913 0.19 
NE-6 0.949 0.895 0.996 0.909 0.39 
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Fig. 7: Droplet size range of optimized formula (NE-4) 
 
 
Fig. 8: Zeta potential value of optimized formula (NE-4) 
 
 
Fig. 9: Droplets morphology of optimized formula (NE-4) 
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Fig. 10: Cumulative distribution chart of droplets in optimized formula (NE-4) 
 
CONCLUSION  
In summary, the nanoemulsion delivery system can be considered as 
an innovative way of improving the water solubility of lipophilic. In 
this study, formula (NE-4) with S mix of (3:1) was the optimized 
formula, which has shown a high solubility of candesartan cilexetil in 
garlic oil, and a high percent cumulative of drug release as compared 
with other formulas. This formular could be a promising formula to 
improve water solubility of candesartan cilexetil and hence, 
bioavailability.  
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